BEGIN:VCALENDAR VERSION:2.0 PRODID:-//34.110.175.232//NONSGML kigkonsult.se iCalcreator 2.26.9// CALSCALE:GREGORIAN METHOD:PUBLISH X-FROM-URL:https://surgerycalendars.stanford.edu X-WR-TIMEZONE:America/Los_Angeles BEGIN:VTIMEZONE TZID:America/Los_Angeles X-LIC-LOCATION:America/Los_Angeles BEGIN:STANDARD DTSTART:20231105T020000 TZOFFSETFROM:-0700 TZOFFSETTO:-0800 RDATE:20241103T020000 TZNAME:PST END:STANDARD BEGIN:DAYLIGHT DTSTART:20240310T020000 TZOFFSETFROM:-0800 TZOFFSETTO:-0700 RDATE:20250309T020000 TZNAME:PDT END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT UID:ai1ec-2794@surgerycalendars-prod.med.stanford.edu DTSTAMP:20240328T130247Z CATEGORIES;LANGUAGE=en-US:Surgery Grand Rounds CONTACT: DESCRIPTION: DTSTART;TZID=America/Los_Angeles:20220405T070000 DTEND;TZID=America/Los_Angeles:20220405T080000 SEQUENCE:0 SUMMARY:Seed Grant Updates Part 1 URL:https://surgerycalendars.stanford.edu/event/seed-grant-updates-part-1/ X-COST-TYPE:free X-TAGS;LANGUAGE=en-US:innovation END:VEVENT BEGIN:VEVENT UID:ai1ec-2797@surgerycalendars-prod.med.stanford.edu DTSTAMP:20240328T130247Z CATEGORIES;LANGUAGE=en-US:Surgery Grand Rounds CONTACT: DESCRIPTION: DTSTART;TZID=America/Los_Angeles:20220503T070000 DTEND;TZID=America/Los_Angeles:20220503T080000 SEQUENCE:0 SUMMARY:Seed Grant Updates Part II URL:https://surgerycalendars.stanford.edu/event/seed-grant-updates-part-ii/ X-COST-TYPE:free X-TAGS;LANGUAGE=en-US:innovation END:VEVENT BEGIN:VEVENT UID:ai1ec-2798@surgerycalendars-prod.med.stanford.edu DTSTAMP:20240328T130247Z CATEGORIES;LANGUAGE=en-US:Surgery Grand Rounds CONTACT: DESCRIPTION: DTSTART;TZID=America/Los_Angeles:20220517T070000 DTEND;TZID=America/Los_Angeles:20220517T080000 SEQUENCE:0 SUMMARY:Seed Grant Updates Part III URL:https://surgerycalendars.stanford.edu/event/seed-grant-updates-part-iii / X-COST-TYPE:free X-TAGS;LANGUAGE=en-US:innovation END:VEVENT BEGIN:VEVENT UID:ai1ec-3329@surgerycalendars-prod.med.stanford.edu DTSTAMP:20240328T130247Z CATEGORIES;LANGUAGE=en-US:Stanford Byers Center for Biodesign CONTACT:bit.ly/FogartyWebinar2022 DESCRIPTION:Mir Imran has accepted the invitation to be the 24th annual Fog arty guest lecturer. The date of the event is Friday September 30\, 2022 at 4pm. It will be a hybrid event.\nMir Imran\, Chairman & CEO of InCube Labs\, is a prolific healthcare innovator and entrepreneur\, who has been developing and commercializing breakthrough medical innovations for over 4 0 years.\nMir began his career as a healthcare entrepreneur in the late 19 70’s with his pioneering contributions to the first FDA-approved Implantab le Defibrillator (ICD). Since then\, Mir has founded more than 20 life sci ences companies and two tech companies\, 15 of which have seen liquidity e vents (IPO/Acquisition). His most recent exit\, Rani Therapeutics Holdings Inc.\, went public on Nasdaq in July 2021.\nMir’s inventions have saved t he lives of millions of patients\, and many have become the standards of c are. He has developed innovative therapies for a number of chronic disease s\, including\, anemia\, chronic pain\, stroke\, diabetes\, and several ca rdiovascular conditions. His recent company\, Rani Therapeutics\, is revol utionizing the management of chronic diseases\, by replacing painful injec table therapies with oral biologics.\nMir holds more than 800 issued & pen ding US patents. In 2016\, QMed named Mir as one of the “Top 50 Medical In ventors of All Time”. Mir is a fellow of the National Academy of Engineeri ng\, the National Academy of Inventors and the American Institute of Medic al & Biological Engineers. In 2009\, Mir was inducted into the Rutgers Uni versity Hall of Distinguished Alumni.\nMir is also the co-founder & managi ng director of InCube Ventures\, LP\, a medtech/biotech venture capital fu nd. In addition\, Mir serves on the boards of several life science compani es\, on the advisory board of the Lemelson Foundation\, and is a trustee o f the UCSC Foundation. He is also an Adjunct Professor of Bioengineering a t the University of Pittsburgh and actively supports the promotion and tea ching of innovation and entrepreneurship at colleges and universities. As a philanthropist\, Mir is passionately supporting education in India and U S\, especially for underprivileged students. DTSTART;TZID=America/Los_Angeles:20220930T160000 DTEND;TZID=America/Los_Angeles:20220930T170000 SEQUENCE:0 SUMMARY:24th Annual Fogarty Lecture URL:https://surgerycalendars.stanford.edu/event/24th-annual-fogarty-lecture / X-COST-TYPE:free X-WP-IMAGES-URL:thumbnail\;https://surgerycalendars.stanford.edu/wp-content /uploads/2022/06/Webinar-Mir-Imran-Fogarty-Lecture-2022-225x300.jpg\;225\; 300\,medium\;https://surgerycalendars.stanford.edu/wp-content/uploads/2022 /06/Webinar-Mir-Imran-Fogarty-Lecture-2022-225x300.jpg\;225\;300\,large\;h ttps://surgerycalendars.stanford.edu/wp-content/uploads/2022/06/Webinar-Mi r-Imran-Fogarty-Lecture-2022-225x300.jpg\;225\;300\,full\;https://surgeryc alendars.stanford.edu/wp-content/uploads/2022/06/Webinar-Mir-Imran-Fogarty -Lecture-2022-225x300.jpg\;225\;300 X-ALT-DESC;FMTTYPE=text/html:\\n\\n
\\nMir Imran has acc epted the invitation to be the 24th annual Fogarty guest lectur er. The date of the event is Friday September 30\, 2022 at 4pm. It will be a hybrid event.
\nMir Imran\, Chairman & CEO of InCube Labs\, is a prolific healthcare innovator and entrepreneur\, who has been developing and commercializing breakthrough medical innovations for over 40 years. p>\n
Mir began his career as a healthcare entrepreneur in the late 1970’ s with his pioneering contributions to the first FDA-approved Implantable Defibrillator (ICD). Since then\, Mir has founded more than 20 life scienc es companies and two tech companies\, 15 of which have seen liquidity even ts (IPO/Acquisition). His most recent exit\, Rani Therapeutics Holdings In c.\, went public on Nasdaq in July 2021.
\nMir’s inventions have sav ed the lives of millions of patients\, and many have become the standards of care. He has developed innovative therapies for a number of chronic dis eases\, including\, anemia\, chronic pain\, stroke\, diabetes\, and severa l cardiovascular conditions. His recent company\, Rani Therapeutics\, is r evolutionizing the management of chronic diseases\, by replacing painful i njectable therapies with oral biologics.
\nMir holds more than 800 i ssued & pending US patents. In 2016\, QMed named Mir as one of the “Top 50 Medical Inventors of All Time”. Mir is a fellow of the National Academy o f Engineering\, the National Academy of Inventors and the American Institu te of Medical & Biological Engineers. In 2009\, Mir was inducted into the Rutgers University Hall of Distinguished Alumni.
\nMir is also the c o-founder & managing director of InCube Ventures\, LP\, a medtech/biotech venture capital fund. In addition\, Mir serves on the boards of several li fe science companies\, on the advisory board of the Lemelson Foundation\, and is a trustee of the UCSC Foundation. He is also an Adjunct Professor o f Bioengineering at the University of Pittsburgh and actively supports the promotion and teaching of innovation and entrepreneurship at colleges and universities. As a philanthropist\, Mir is passionately supporting educat ion in India and US\, especially for underprivileged students.
\n X-TAGS;LANGUAGE=en-US:Guest Lecturer\,innovation END:VEVENT BEGIN:VEVENT UID:ai1ec-3379@surgerycalendars-prod.med.stanford.edu DTSTAMP:20240328T130247Z CATEGORIES;LANGUAGE=en-US:Department-wide events\,Surgery Grand Rounds CONTACT: DESCRIPTION: DTSTART;TZID=America/Los_Angeles:20230530T070000 DTEND;TZID=America/Los_Angeles:20230530T080000 SEQUENCE:0 SUMMARY:Seed Grant Updates: Aarons Dawes & Kazunari Sasaki URL:https://surgerycalendars.stanford.edu/event/seed-grant-updates-aarons-d awes-kazunari-sasaki/ X-COST-TYPE:free X-TAGS;LANGUAGE=en-US:innovation END:VEVENT END:VCALENDAR